• Does an SVR to Therapy for HCV-associated Cirrhosis Reduce Portal Pressure?

Does an SVR to Therapy for HCV-associated Cirrhosis Reduce Portal Pressure?

A sustained virologic response (SVR) to all-oral therapy in patients with hepatitis C virus (HCV)-associated cirrhosis significantly reduces the hepatic venous pressure gradient (HVPG), researchers report in the November issue of Gastroenterology. Nevertheless, almost 80% of patients maintain significant portal hypertension and have a continued risk of decompensation. In patients with compensated

Read more

Can Circulating Membrane Vesicles Promote Portal Hypertension?

Patients with cirrhosis have a large amount of circulating membrane vesicles—breakdown products from inflammation and liver cell damage. However, these ‘microparticles’ (MPs) are not simply debris; they contribute to the systemic vasodilation and portal hypertension associated with cirrhosis, according to the July issue of Gastroenterology. Patients with cirrhosis have persistent

Read more